KROS Keros Therapeutics, Inc.

NASDAQ
$11.26

Keros Therapeutics, Inc. (KROS) SEC Filings

Everything KROS has filed with the SEC, newest first. An 8-K shows what it was about where we have classified it — an earnings release and a change of chief executive are both 8-Ks, and the form number alone doesn't separate them.

62 filings
Date Form Filing
8-K Material Agreement · Reg Fd View filing
8-K Other Reg Fd · Reg Fd View filing
8-K Capital Raise · Material Agreement · Other Event View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
144 View filing
10-Q View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
10-Q View filing
4 View filing
4 View filing
4/A View filing
4 View filing
4 View filing
10-K View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
4 View filing
10-Q View filing
4 View filing
4 View filing
4 View filing
10-Q View filing
10-Q View filing
10-K View filing
10-Q View filing
10-Q View filing
10-Q View filing
10-K View filing
10-Q View filing
10-Q View filing
10-Q View filing
10-K View filing
10-Q View filing
10-Q View filing
10-Q View filing
10-K View filing
10-Q View filing

Filings are sourced from EDGAR and open on the SEC's own site. Classification of 8-K events is ours and is not part of the filing.